Iran permits voluntary injection of Noora vaccine in emergency
(MENAFN- Trend News Agency)
Food and Drug Administration of Iran has granted permission for
receiving home-made Noora vaccine as booster shot and in emergency
cases, Trend reports citing IRNA .
About the news, Head of Food and Drug Administration Bahram
Daraei said the permission was given to Noora coronavirus vaccine
after Barekat, PastoCovac, Razi Cov Pars, Spicogen, and Fakhra.
Noora is a recombinant vaccine produced by Iranian researchers,
doctors, and experts.
The vaccine can be used as a booster shot.
About Noora, Dean of Iran's Baqiyatallah University of Medical
Sciences Hassan Abolqasemi said that five million doses of the
vaccine have been produced and are ready to be delivered to
Ministry of Health and Medical Education.
Reportedly, Iran's Barekat Foundation conducted human trial of
COVID-19 vaccine by injecting it to the first volunteer at the
first phase on December 29, 2020.
In a related development, the third phase of double-blind
clinical trial of Iranian-Cuban COVID-19 vaccine started in central
Iranian city of Isfahan in April, 2021.
Once, director general of Pasteur Institute of Iran (IPI) said
the IPI is the first institute in West Asia to embark on producing
COVID vaccine.
According to the IPI website, Pasteur Institute of Iran was
founded in the heart of Iran's capital, Tehran, in the 1920s to
pave the way for advanced research and to provide innovative
programs in basic and applied medical sciences, and production of
biopharmaceuticals and diagnostic kits with special emphasis on
infectious diseases.
Since its outbreak in December 2019, the coronavirus pandemic
has killed over 6,000,000 people worldwide.
MENAFN08032022000187011040ID1103814086
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.